Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, recently presented preclinical data showing its proprietary ...

ADCs integrate monoclonal antibodies with cytotoxic payloads, offering new treatment options for NSCLC, including biomarker-selected and biomarker-agnostic patients. ADCs are composed of an antibody, ...

Neuroendocrine tumors (NETs) are difficult to treat due to their high heterogeneity and complexity. SEZ6 (Seizure-related 6 homolog) is a key regulator of dendritic formation and neural signaling and ...

Akari Therapeutics (AKTX) announced the presentation of immune mechanism-of-action data for its novel ADC payload, PH1. The Company will host a live webcast to discuss the presented data on Tuesday, ...